Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
Information source: VU University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Delirium; Advanced Cancer
Intervention: Olanzapine (Drug); Haloperidol (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: VU University Medical Center Official(s) and/or principal investigator(s):
Henk MW Verheul, MD, PhD, Principal Investigator, Affiliation: VU University Medical Center
Overall contact:
Henk MW Verheul, MD, PhD, Phone: +31-20-4444321, Email: h.verheul@vumc.nl
Summary
The investigators designed a randomised multicenter clinical trial for patients with
advanced cancer who are admitted to the medical oncology ward or high-care hospice. On
admission all patients with advanced cancer will be asked to participate in this study.
Consenting patients will be submitted to delirium observation screening according to the
DOS. Subsequently DOS screening will be performed twice weekly until discharge. Each patient
who's score is > 3 (DOS positive) is showing significant symptoms of delirium and will be
submitted to the revised Delirium Rating Scale (DRS-R-98) to confirm diagnosis. To test
validity of the DOS scale for this particular population, each DOS positive score will be
randomly matched with a patient with a DOS score < 3 (DOSnegative) and this patient will
also be submitted to DRS-R-98. When diagnosis of delirium is confirmed by DRS-98, patients
will be randomised between treatment of delirium with olanzapine or haloperidol (usual
care). Treatment in both groups will consist of identification and management of underlying
aetiologies of delirium if possible and adding neuroleptic medication for symptom control.
Patients who recover from their delirium episode as well as their caregivers will be asked
to complete the Delirium Experience Questionnaire (DEQ) to assess recall of the delirium
experience and the degree of distress related to the delirium episode.
Clinical Details
Official title: Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: DRS-R-98 severity rating score
Secondary outcome: Delirium resolution rate
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient has been diagnosed with advanced cancer
- Age ≥ 18
- Patient or his / her significant other speaks Dutch fluently
Exclusion Criteria:
- Delirium is due to alcohol withdrawal
- Patient has been diagnosed with glaucoma, Parkinson's disease or dementia
- Patient is being treated with other neuroleptic medication or lithium
- Patient has another psychiatric disorder that is considered (by investigator) to
interfere with assessment of delirium
- Patient had a QTc-interval of > 480 msec on ECG made on admission to the medical
oncology ward (ECG is not required if patient is admitted to a high-care hospice)
- Patient has a history of neuroleptic malignant syndrome
- Patient has a history of convulsions.
Locations and Contacts
Henk MW Verheul, MD, PhD, Phone: +31-20-4444321, Email: h.verheul@vumc.nl
VU University Medical Center, Amsterdam 1081HV, Netherlands; Recruiting
Henk MW Verheul, MD, PhD, Phone: +31-20-4444321, Email: h.verheul@vumc.nl
Henk MW Verheul, MD, PhD, Principal Investigator
Maurice Van der Vorst, MD, Sub-Investigator
Liesbeth Neefjes, MD, Sub-Investigator
Spaarne Hospital, Hoofddorp, Netherlands; Recruiting
Aart Beeker, MD, Phone: +31-23-8907166, Email: abeeker@spaarneziekenhuis.nl
Aart Beeker, MD, Principal Investigator
Additional Information
Starting date: March 2010
Last updated: June 2, 2015
|
